Abstract

The most significant potential risk of radioiodine therapy is bone marrow suppression. Therefore, in the treatment of distant metastases, lesion-based dosimetry is evaluated in conjunction with bone marrow dosimetry. It has been reported that an absorbed dose of at least 80 Gray (Gy) is required to effectively eradicate metastases. For this reason, in lesion-based dosimetry, the iodine-131 activity is calculated individually for each patient to deliver a minimum dose of 80 Gy to the tumor.